Cellectar Biosciences, Inc. financial data

Symbol
CLRB on Nasdaq
Location
100 Campus Drive, Florham Park, NJ
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 250 % +93%
Debt-to-equity 75.6 % -79.4%
Return On Equity -206 % +74.4%
Return On Assets -108 % +34.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.24M shares -89.5%
Common Stock, Shares, Outstanding 3.19M shares -92.1%
Entity Public Float 89.1M USD +371%
Common Stock, Value, Issued 32 USD -92.1%
Weighted Average Number of Shares Outstanding, Basic 3.16M shares +141%
Weighted Average Number of Shares Outstanding, Diluted 3.16M shares +138%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 14.5M USD -47.4%
General and Administrative Expense 15.5M USD -35.3%
Costs and Expenses 30M USD -41.8%
Operating Income (Loss) -30M USD +41.8%
Nonoperating Income (Expense) 11.2M USD +696%
Net Income (Loss) Attributable to Parent -18.9M USD +62.4%
Earnings Per Share, Basic 6 USD/shares +87.4%
Earnings Per Share, Diluted 12 USD/shares +88.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 12.6M USD -63.4%
Assets, Current 13.6M USD -62.1%
Property, Plant and Equipment, Net 595K USD -34.6%
Operating Lease, Right-of-Use Asset 381K USD -16.1%
Other Assets, Noncurrent 29.8K USD 0%
Assets 14.6M USD -60.8%
Accounts Payable, Current 4.11M USD -27%
Liabilities, Current 4.91M USD -75.8%
Operating Lease, Liability, Noncurrent 336K USD -22.2%
Liabilities 5.25M USD -74.7%
Retained Earnings (Accumulated Deficit) -264M USD -7.7%
Stockholders' Equity Attributable to Parent 8M USD -47.3%
Liabilities and Equity 14.6M USD -60.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.38M USD +29.8%
Net Cash Provided by (Used in) Financing Activities 43.8M USD
Net Cash Provided by (Used in) Investing Activities -21.6K USD
Common Stock, Shares Authorized 170M shares 0%
Common Stock, Shares, Issued 3.19M shares -92.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -9.38M USD -131%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12.6M USD -63.4%
Deferred Tax Assets, Valuation Allowance 107M USD +22.3%
Deferred Tax Assets, Gross 108M USD +22.2%
Operating Lease, Liability 433K USD -15.6%
Payments to Acquire Property, Plant, and Equipment 21.6K USD
Lessee, Operating Lease, Liability, to be Paid 548K USD -20.9%
Property, Plant and Equipment, Gross 1.98M USD +77.8%
Operating Lease, Liability, Current 96K USD +18.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 153K USD +2%
Lessee, Operating Lease, Liability, to be Paid, Year One 150K USD +2.74%
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 115K USD -36.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 156K USD +1.96%
Preferred Stock, Shares Issued 35.6 shares
Preferred Stock, Shares Authorized 1.23K shares
Lessee, Operating Lease, Liability, to be Paid, Year Four 155K USD +1.31%
Additional Paid in Capital 271M USD +10.1%
Preferred Stock, Shares Outstanding 35.6 shares
Depreciation, Depletion and Amortization 56.3K USD -36.4%
Deferred Tax Assets, Net of Valuation Allowance 107M USD +22.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%